Cumberland director reports automatic stock purchases

Cumberland Pharmaceuticals director Kenneth J. Krogulski reported a series of small open-market purchases of the company’s common stock in December 2025.

Rhea-AI Filing Summary

Cumberland Pharmaceuticals director Kenneth J. Krogulski reported a series of small open-market purchases of the company’s common stock in December 2025. The transactions, coded “L,” were executed under a Rule 10b5-1 trading plan that he adopted on November 14, 2024. Individual daily purchases ranged from dozens of shares at prices in the low single digits per share. The most recent reported transaction was on December 31, 2025, when he bought 62 shares at $3.91 each, bringing his directly held stake to 296,538 common shares following that trade.

Insider Trade Summary

Small Acquisition: 1,916 shares

Small Acquisition 22 txns

Insider Krogulski Kenneth

Role Director

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock	62	$3.91	$242.42
Small Acquisition	Common Stock	54	$3.94	$212.76
Small Acquisition	Common Stock	54	$4.01	$216.54
Small Acquisition	Common Stock	54	$4.21	$227.34
Small Acquisition	Common Stock	54	$4.26	$230.04
Small Acquisition	Common Stock	54	$4.13	$223.02
Small Acquisition	Common Stock	50	$4.32	$216.00
Small Acquisition	Common Stock	52	$4.19	$217.88
Small Acquisition	Common Stock	67	$4.19	$280.73
Small Acquisition	Common Stock	67	$3.65	$244.55
Small Acquisition	Common Stock	104	$3.27	$340.08
Small Acquisition	Common Stock	104	$2.82	$293.28
Small Acquisition	Common Stock	104	$2.50	$260.00
Small Acquisition	Common Stock	104	$2.56	$266.24
Small Acquisition	Common Stock	104	$2.60	$270.40
Small Acquisition	Common Stock	104	$2.32	$241.28
Small Acquisition	Common Stock	104	$2.40	$249.60
Small Acquisition	Common Stock	124	$2.34	$290.16
Small Acquisition	Common Stock	124	$2.27	$281.48
Small Acquisition	Common Stock	124	$2.25	$279.00
Small Acquisition	Common Stock	124	$2.24	$277.76
Small Acquisition	Common Stock	124	$2.36	$292.64

Holdings After Transaction: Common Stock — 296,538 shares (Direct)

Footnotes (1)

1. F1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did CPIX report for Kenneth Krogulski?

The filing shows that director Kenneth J. Krogulski made multiple small open-market purchases of Cumberland Pharmaceuticals (CPIX) common stock throughout December 2025.

How many Cumberland Pharmaceuticals shares does the director own after these trades?

After the December 31, 2025 transaction, Kenneth J. Krogulski beneficially owned 296,538 shares of Cumberland Pharmaceuticals common stock, held directly.

At what price was the latest CPIX insider purchase made?

On December 31, 2025, the latest reported trade, the director purchased 62 shares of Cumberland Pharmaceuticals common stock at $3.91 per share.

Were these CPIX insider trades made under a Rule 10b5-1 plan?

Yes. A footnote states that the reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Is Kenneth Krogulski a director or officer of Cumberland Pharmaceuticals?

The filing identifies Kenneth Krogulski as a director of Cumberland Pharmaceuticals and not as an officer or 10% owner.

Are the CPIX shares held directly or indirectly by the reporting person?

The Form 4 shows the holding as direct ownership (D) with no indicated indirect ownership vehicle for the reported common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krogulski Kenneth

(Last) (First) (Middle)

1600 WEST END AVE., SUITE 1300

(Street)

NASHVILLE TN 37203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/01/2025		L	V	124(1)	A	$2.36	294,746	D
Common Stock	12/02/2025		L	V	124(1)	A	$2.24	294,870	D
Common Stock	12/03/2025		L	V	124(1)	A	$2.25	294,994	D
Common Stock	12/04/2025		L	V	124(1)	A	$2.27	295,118	D
Common Stock	12/05/2025		L	V	124(1)	A	$2.34	295,242	D
Common Stock	12/08/2025		L	V	104(1)	A	$2.4	295,346	D
Common Stock	12/09/2025		L	V	104(1)	A	$2.32	295,450	D
Common Stock	12/10/2025		L	V	104(1)	A	$2.6	295,554	D
Common Stock	12/11/2025		L	V	104(1)	A	$2.56	295,658	D
Common Stock	12/12/2025		L	V	104(1)	A	$2.5	295,762	D
Common Stock	12/15/2025		L	V	104(1)	A	$2.82	295,866	D
Common Stock	12/16/2025		L	V	104(1)	A	$3.27	295,970	D
Common Stock	12/17/2025		L	V	67(1)	A	$3.65	296,037	D
Common Stock	12/18/2025		L	V	67(1)	A	$4.19	296,104	D
Common Stock	12/19/2025		L	V	52(1)	A	$4.19	296,156	D
Common Stock	12/22/2025		L	V	50(1)	A	$4.32	296,206	D
Common Stock	12/23/2025		L	V	54(1)	A	$4.13	296,260	D
Common Stock	12/24/2025		L	V	54(1)	A	$4.26	296,314	D
Common Stock	12/26/2025		L	V	54(1)	A	$4.21	296,368	D
Common Stock	12/29/2025		L	V	54(1)	A	$4.01	296,422	D
Common Stock	12/30/2025		L	V	54(1)	A	$3.94	296,476	D
Common Stock	12/31/2025		L	V	62(1)	A	$3.91	296,538	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	Kenneth J. Krogulski by /s/ John Hamm as attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.